Dot blot analysis of AAV3, AAV7, AAV8, AAVrh10 and AAVrh74 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV8 antibody clone ADK8 and human chimeric AAV8 antibody clone ADK8-h1.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV8 (intact particle) mouse monoclonal, ADK8 (Cat. No. 610160) or anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgG goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV8 with mouse monoclonal AAV8 antibody clone ADK8 (A) and human chimeric AAV8 antibody clone ADK8-h1 (B) by using AAV8-NanoLuc® viral particles from Promega. (A) anti-AAV8 (intact particle) mouse monoclonal, ADK8 or (B) anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) were preincubated with AAV8-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Neutralization of AAV3 with mouse monoclonal AAV8 antibody clone ADK8 (A) and human chimeric AAV8 antibody clone ADK8-h1 (B) by using AAV3-NanoLuc® viral particles from Promega. (A) anti-AAV8 (intact particle) mouse monoclonal, ADK8 or (B) anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) were preincubated with AAV3-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Comparison of binding affinity and neutralization activity of anti-AAV8 antibodies (mouse monoclonal ADK8 and human chimeric ADK8-h1).
Dot blot analysis of AAV3, AAV7, AAV8, AAVrh10 and AAVrh74 native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids with mouse monoclonal AAV8 antibody clone ADK8 and human chimeric AAV8 antibody clone ADK8-h1.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV8 (intact particle) mouse monoclonal, ADK8 (Cat. No. 610160) or anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-mouse IgG goat polyclonal, HRP conjugate or anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1.5 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Neutralization of AAV8 with mouse monoclonal AAV8 antibody clone ADK8 (A) and human chimeric AAV8 antibody clone ADK8-h1 (B) by using AAV8-NanoLuc® viral particles from Promega. (A) anti-AAV8 (intact particle) mouse monoclonal, ADK8 or (B) anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) were preincubated with AAV8-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Neutralization of AAV3 with mouse monoclonal AAV8 antibody clone ADK8 (A) and human chimeric AAV8 antibody clone ADK8-h1 (B) by using AAV3-NanoLuc® viral particles from Promega. (A) anti-AAV8 (intact particle) mouse monoclonal, ADK8 or (B) anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) were preincubated with AAV3-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.
Dot blot analysis of AAV1-AAV9, AAVrh10, AAVrh74, AAVDJ native (1E+09-1E+10 capsids) and denatured (1E+10 capsids, denatured at 95°C for 10 min in sample buffer) capsids.
The nitrocellulose membrane was blocked with 5% milk in PBST for 45 min at RT. The primary antibody anti-AAV8, human chimeric, ADK8-h1 (Cat. No. 692318) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1.5 h at RT. The secondary antibody anti-human IgG goat polyclonal, HRP conjugate was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce™ ECL Western Blotting Substrate.
Comparison of binding affinity and neutralization activity of anti-AAV8 antibodies (mouse monoclonal ADK8 and human chimeric ADK8-h1).
- Recombinant chimeric (human Fc region)
- Suitable for dot blot, neutralization assay and serology ELISA
- Reacts with AAV3, AAV7, AAV8, AAVrh10 and AAVrh74 intact capsids
- Isotype: IgG1
Product description
| Quantity | 1 ml |
|---|---|
| Antibody Type | Monoclonal |
| Host | Recombinant chimeric (human Fc region) |
| Isotype | IgG1 |
| Conjugate | Unconjugated |
| Application | Dot blot, Neutralization assay, Serology ELISA |
| Purification | Affinity chromatography |
| Reactivity | AAV3, AAV7, AAV8, AAVrh10, AAVrh74 |
| No reactivity | AAV1, AAV2, AAV4, AAV5, AAV6, AAV9, AAVDJ |
| Storage | 2-8°C |
| Intended use | Research use only |
| Clone | ADK8-h1 |
| Immunogen | AAV8 capsids |
| Concentration | 50 µg/ml |
| Formulation | PBS, pH 7.4 with 0.09% sodium azide and 0.5% BSA |
| Binding affinity | KD value (AAV8) = <1.0E-12 M KD value (AAVrh10) = <1.0E-12 M KD value (AAVrh74) = <1.0E-12 M |
| Synonym | Adeno-associated virus 8; AAV-8 |
Applications
| Tested applications | Tested dilutions |
|---|---|
| Serology Assay | 0.1-0.4 µg/ml (1:125-1:500; AAV8 ELISA) |
| Dot Blot | 0.1 µg/ml (1:500; non-denaturing conditions) |
| Neutralization Assay | EC50 ~26 ng/ml (AAV3), ~2 ng/ml (AAV8) - assay dependent |
Background
Our human chimeric AAV antibodies are derived from our mouse monoclonal AAV antibodies and are a combination of the mouse antigen binding region and a human Fc region. Therefore, it provides the well-known characteristics of the corresponding mouse monoclonal antibody (anti-AAV8, ADK8, Cat. No. 610160) like cross-reactivity and neutralization activity combined with a human Fc region allowing the use in an anti-human secondary antibody detection system.
Many humans in the general population have developed antibodies against AAV as a result of naturally acquired infections, which might affect efficacy and safety of the gene transfer using AAV vectors. Therefore, testing for pre-existing AAV antibodies in patient sera is an indispensable step for the selection of patients for AAV gene therapy clinical trials.
Our human chimeric AAV antibodies are close to the human derived samples, making them the ideal positive control for reproducible and comparable serological assays.
Limited Use Label License: Research Use Only
Product is exclusively owned to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.
Downloads
Customer Reviews
Login
FAQs
The human chimeric AAV antibodies have the same variable region as our mouse monoclonal antibodies but instead a human constant region.
Yes, they show the same cross-reactivity as their mouse monoclonal versions. The table below shows where cross-reactivity takes place.
| Human Chimeric Antibody | Clone | AAV1 | AAV2 | AAV3 | AAV4 | AAV5 | AAV6 | AAV7 | AAV8 | AAV9 | AAVrh10 | AAVrh74 | AAVDJ |
| Anti-AAV1 | ADK1a-h1 | X | X | n.a.* | |||||||||
| Anti-AAV2 | A20-h1 | X | X | n.a.* | |||||||||
| Anti-AAV5 | ADK5b-h1 | X | n.a.* | ||||||||||
| Anti-AAV5 | ADK5b-h2 | X | n.a.* | ||||||||||
| Anti-AAV8 | ADK8-h1 | X | X | X | X | X | |||||||
| Anti-AAV9 | ADK9-h1 | n.a.* | X |
*n.a.: not analyzed
The binding affinity of the human chimeric antibodies to different AAV serotypes was tested and compared to the corresponding mouse monoclonal antibodies using biolayer interferometry (BLI) analysis. The table below shows the results.
| Serotype | Antibody Clone | Binding Affinity (KD Value) |
| AAV1 | ADK1a | <1.0E-12 M |
| ADK1a-h1 | 8.8E-12 M | |
| AAV2 | A20 | 2.6E-11 M |
| A20-h1 | 1.2E-10 M | |
| A20R | <1.0E-12 M | |
| AAV3 | A20 | <1.0E-12 M |
| A20-h1 | 9.3E-11 M | |
| A20R | <1.0E-12 M | |
| AAV5 | ADK5a | 4.9E-11 M |
| ADK5b | 6.0E-11 M | |
| ADK5b-h1 | 8.1E-11 M | |
| ADK5b-h2 | 3.6E-11 M | |
| AAV6 | ADK1 | <1.0E-12 M |
| ADK1a-h1 | 5.9E-11 M | |
| AAV8 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M | |
| AAV9 | ADK9-1R | <1.0E-12 M |
| ADK9-h1 | 7.0E-11 M | |
| AAVrh10 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M | |
| AAVrh74 | ADK8 | <1.0E-12 M |
| ADK8-h1 | <1.0E-12 M |
The lower the KD value the higher the binding affinity. The detection limit is 1.0E-12 M.
Related Products
